Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Overweight or Obesity
Atrial Fibrillation

Interventions

DRUG: Semaglutide
DRUG: Placebo

Sponsor

University of Chicago